Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2000
06/02/2000WO2000031033A1 Piperidine ccr-3 receptor antagonists
06/02/2000WO2000031032A1 Pyrrolidine derivatives-ccr-3 receptor antagonists
06/02/2000WO2000030715A1 Composition containing an analgesic and a xanthine or a xanthine derivative
06/02/2000WO2000030694A1 Coating useful as a dispenser of an active ingredient on dressings and bandages
06/02/2000WO2000030684A1 Medicinal compositions for periodic administration
06/02/2000WO2000030683A1 Preventives and/or remedies for central nervous system diseases containing compounds having txa2 receptor antagonism and/or txa2 synthase inhibitory effect
06/02/2000WO2000030682A1 Khellin preparation and the use thereof for topical therapy
06/02/2000WO2000030671A2 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
06/02/2000WO2000030666A1 Composition and methods for inhibiting the formation of brain amyloid deposits
06/02/2000WO2000030665A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
06/02/2000WO2000030664A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
06/02/2000WO2000030663A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases
06/02/2000WO2000030660A2 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
06/02/2000WO2000030657A1 A process for producing an iron-dextran compound
06/02/2000WO2000030654A1 Anti-asthmatic combinations comprising surface active phospholipids
06/02/2000WO2000030653A2 Use of phosphonoformic acid derivatives for treating infections
06/02/2000WO2000030652A1 Use of dehydroepiandrosterone for increasing the number of nmda receptors in a mammal
06/02/2000WO2000030651A1 Use of staurosporine derivatives for treating ocular neovascular diseases
06/02/2000WO2000030650A1 Desmethylolanzapine compositions and methods
06/02/2000WO2000030649A1 Pharmaceutical compositions containing olanzapine-n-oxide
06/02/2000WO2000030648A1 2-hydroxymethylolanzapine compositions and methods
06/02/2000WO2000030647A1 Compositions comprising cefuroxime axetil
06/02/2000WO2000030646A1 Heterocyclic compounds regulating clotting
06/02/2000WO2000030645A1 Agent for prophylaxis and treatment of panic disorder
06/02/2000WO2000030644A1 Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
06/02/2000WO2000030643A1 Novel therapeutic application of nicergoline
06/02/2000WO2000030642A1 Use of nicergoline for treating spasmodism
06/02/2000WO2000030641A1 Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption
06/02/2000WO2000030640A1 Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
06/02/2000WO2000030639A1 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
06/02/2000WO2000030638A1 Drugs and reagents containing n-acyloxylated cycloalkyl compounds as the active ingredient
06/02/2000WO2000030637A1 Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
06/02/2000WO2000030636A1 Use of pyrethroid compounds to promote hair growth
06/02/2000WO2000030635A1 Composition and use of rar antagonists for promoting chondrogenesis
06/02/2000WO2000030634A1 Oral creatine supplementation for treating or preventing muscle disuse syndrome
06/02/2000WO2000030633A1 Method of treating chronic obstructive pulmonary disease
06/02/2000WO2000030632A1 Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists
06/02/2000WO2000030631A1 Use of diminazene-di-aceturate for treating malaria
06/02/2000WO2000030630A1 Combination products of a guanylate cyclase inhibitor and a local anesthetic for pain relief
06/02/2000WO2000030629A2 Method of promoting cervical and vaginal secretions
06/02/2000WO2000030628A2 Method of inhibiting angiogenesis
06/02/2000WO2000030627A2 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
06/02/2000WO2000030626A2 Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
06/02/2000WO2000030625A2 Use of phosphonoformic acid derivatives for treating infections
06/02/2000WO2000030624A2 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
06/02/2000WO2000030623A2 Agent for lowering prolactin
06/02/2000WO2000030622A2 Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
06/02/2000WO2000030620A1 Solid lipidic nanospheres suitable to a fast internalization into cells
06/02/2000WO2000030619A1 Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
06/02/2000WO2000030618A1 Particles based on polyamino-acid(s) and methods for preparing same
06/02/2000WO2000030614A1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
06/02/2000WO2000030613A1 New process
06/02/2000WO2000030612A1 A method of producing drug particles
06/02/2000WO2000030611A2 Pharmaceutical preparation
06/02/2000WO2000030608A1 Pressurised metered dose inhalers (mdi)
06/02/2000WO2000030598A1 Low-irritation antiperspirant and deodorant compositions
06/02/2000WO2000030590A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
06/02/2000WO2000030587A2 NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES
06/02/2000WO2000030578A1 Enzymatic treatment and prevention of hypertrophic skin
06/02/2000WO2000030477A1 Beverage for increasing the body's capacity to break down alcohol
06/02/2000WO2000030449A1 Antiparasitic formulations
06/02/2000WO2000030446A1 Dosage formulations for acetylcholinesterase inhibitors
06/02/2000WO2000030425A2 Method of using pon-1 to decrease atheroma formation
06/02/2000WO2000018388A3 Antibiotic compositions for treatment of the eye, ear and nose
06/02/2000WO2000014244A3 Treatment of cervical cancer
06/02/2000WO2000013691A3 3-deazaadenosine prevents atherosclerosis and graft vasculopathy
06/02/2000WO2000013682A3 4-quinolinemethanol derivatives as purine receptor antagonists.(ii)
06/02/2000WO2000010999A3 New compounds
06/02/2000WO2000010610A3 Drug targeting
06/02/2000WO2000010605A3 Preventives or remedies for eye circulatory failure
06/02/2000WO2000010506A3 Angiogenesis inhibitors and uses thereof
06/02/2000WO2000010391A8 The use of adenosine a3 receptor antagonists to inhibit tumor growth
06/02/2000WO2000009105A3 Small molecule carbamates or ureas for vision and memory disorders
06/02/2000WO1999064594A8 Genes and gene expression products that are differentially regulated in prostate cancer
06/02/2000WO1999063095A9 Nucleic acid vaccines for prevention of flavivirus infection
06/02/2000CA2698376A1 Pressurised metered dose inhalers (mdi)
06/02/2000CA2352611A1 2-hydroxymethylolanzapine compositions and methods
06/02/2000CA2352599A1 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
06/02/2000CA2352585A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
06/02/2000CA2352584A1 Quinoline and quinoxaline compounds
06/02/2000CA2352583A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
06/02/2000CA2352549A1 Use of phosphonoformic acid derivatives for treating infections
06/02/2000CA2352543A1 Method of treating chronic obstructive pulmonary disease
06/02/2000CA2352526A1 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
06/02/2000CA2352511A1 Use of phosphonoformic acid derivatives for treating infections
06/02/2000CA2352510A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases
06/02/2000CA2352485A1 Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
06/02/2000CA2352461A1 Pharmaceutical composition for periodic administration
06/02/2000CA2352338A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
06/02/2000CA2352317A1 Amino alkylphosphonic acid derivatives and their use in treating infections
06/02/2000CA2352278A1 Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
06/02/2000CA2352262A1 Method of promoting cervical and vaginal secretions
06/02/2000CA2352261A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
06/02/2000CA2352215A1 Beverage for increasing the body's alcohol degradation capacity
06/02/2000CA2352154A1 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
06/02/2000CA2352144A1 Scavenger compounds
06/02/2000CA2351980A1 Use of dehydroepiandrosterone for increasing the number of nmda receptors in a mammal
06/02/2000CA2351865A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000CA2351733A1 Nf-kb activation inhibitors, and their pharmaceutical uses
06/02/2000CA2351725A1 Substituted pyrazoles as p38 kinase inhibitors
1 ... 6307 6308 6309 6310 6311 6312 6313 6314 6315 6316 6317 6318 6319 6320 6321 6322 6323 6324 6325 6326 6327 ... 7860